# MeaCor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meacor

- Industry: Medical Devices & Equipment
- Headquarters: Ayer, US
- Website: www.meacor.com
- Latest round: Seed (Jan 1, 2020)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded by Toufic Azar in 2016, MeaCor operates as a medtech company that develops minimally invasive transcatheter devices for the treatment of heart disease. In May 2024, MeaCor raised USD 15 million in series A funding. The firm as of August 2024, is led by its co-founders, Toufic Azar (CEO) and Renzo Cecere (CMO).

Meacor specializes in treating mitral and tricuspid valve regurgitation, a condition where heart valves leak and can lead to heart failure. The company’s CryoCinch system offers a minimally invasive alternative to traditional open-heart surgery. Using cryo-adhesion, the device attaches repair anchors with less risk and faster recovery than conventional methods. This technology is particularly useful for elderly patients or those with multiple health issues. The CryoCinch system aims to reduce tissue damage and may also be used for valve replacement in the future.

The company plans to utilize the May 2024 funding to provide a novel transcatheter approach for the treatment of mitral and tricuspid valve regurgitation.

## Funding rounds

- Seed, Jan 1, 2020 — iSME Programme
- Seed, Jan 1, 2019 — iSME Programme
- Seed, Jun 1, 2016 — iSME Programme

## Investors

- iSME Programme (https://capitalatlas.ai/funds/isme-programme) — Seed